XT
CLDX icon

XTX Topco’s Celldex Therapeutics CLDX Stock Holding History

XTX Topco’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$383K Sell
12,074
-39,449
-77% -$1.08M 0.01% 2271
2025
Q4 		$1.4M Buy
51,523
+43,629
+553% +$1.15M 0.04% 788
2025
Q3 		$204K Sell
7,894
-10,397
-57% -$241K 0.01% 1833
2025
Q2 		$372K Buy
+18,291
New +$356K 0.02% 1301
2025
Q1 		– Sell
-11,256
Closed -$284K – 2493
2024
Q4 		$284K Sell
11,256
-34,661
-75% -$942K 0.02% 1270
2024
Q3 		$1.56M Buy
+45,917
New +$1.75M 0.11% 224
2024
Q2 		– Sell
-5,534
Closed -$232K – 1941
2024
Q1 		$232K Buy
+5,534
New +$227K 0.03% 1058
2023
Q4 		– Sell
-11,159
Closed -$307K – 1663
2023
Q3 		$307K Buy
+11,159
New +$350K 0.05% 712

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return